MARKET

FRTX

FRTX

Fresh Tracks Therapeutics Inc
OTCPK
0.910
+0.010
+1.11%
Closed 15:44 02/23 EST
OPEN
0.900
PREV CLOSE
0.900
HIGH
0.910
LOW
0.900
VOLUME
8.42K
TURNOVER
7.60K
52 WEEK HIGH
3.140
52 WEEK LOW
0.450
MARKET CAP
5.44M
P/E (TTM)
-0.3408
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at FRTX last week (0212-0216)?
Weekly Report · 5d ago
Fresh Tracks Therapeutics Shareholders Vote on Dissolution
TipRanks · 02/16 21:26
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024. Fresh Tracks Therapeutics will hold a special meeting of stockholders on February 15, 2024 to seek stockholder approval of the liquidation and dissolution of the Company.
Barchart · 02/14 11:47
Weekly Report: what happened at FRTX last week (0205-0209)?
Weekly Report · 02/12 09:33
Weekly Report: what happened at FRTX last week (0129-0202)?
Weekly Report · 02/05 09:36
Weekly Report: what happened at FRTX last week (0122-0126)?
Weekly Report · 01/29 09:33
Weekly Report: what happened at FRTX last week (0115-0119)?
Weekly Report · 01/22 09:34
Weekly Report: what happened at FRTX last week (0108-0112)?
Weekly Report · 01/15 09:33
More
About FRTX
Fresh Tracks Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in transforming patient lives through the development of differentiated prescription therapeutics. Its pipeline is focused on providing existing treatment paradigms and features several new chemical entities that inhibit novel targets with potential for autoimmune, inflammatory, and other debilitating diseases. The Company’s strategy is exploring therapies by identifying, pursuing, and developing therapeutics that can help people struggling with autoimmune, inflammatory, and other debilitating diseases. Its pipeline includes FRTX-02, FRTX-10, Next-Generation Kinase Inhibitors and FRTX-03. FRTX-02 is a potential Oral DYRK1A Inhibitor for the treatment of autoimmune and inflammatory diseases. Its FRTX-10 is a covalent Stimulator of Interferon Genes (STING) inhibitor candidate for the potential treatment of autoimmune, inflammatory, and rare genetic diseases.

Webull offers Fresh Tracks Therapeutics Inc stock information, including OTCPK: FRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FRTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FRTX stock methods without spending real money on the virtual paper trading platform.